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Abstract
Background: Atrial fibrillation (AF) decreases left ventricular stroke volume, impaires the
mechanical function of heart valves, and disturbes neurohumoral activity of the miocardium.
This study evaluated the influence of AF on clinical presentation and long-term follow-up of the
patients with systolic heart failure.
Methods: A retrospective analysis of the data on clinical presentation of 152 patients (38 women
and 114 men) with systolic heart failure (EF < 40%) was performed. The following parameters
were compared between patients with and without AF: heart rate and presence of LBBB, several
echocardiographic parameters (EF, LVEDV, size of LA, LVEDd, LVESd), oxygen consumption
per minute, and frequency of end-point’s (death, stroke, rehospitalization, CABG) during mean
936-day follow-up.
Results: The 53 (35%) AF patients in comparison with 99 non-AF were characterized by:
lower exercise performance (VO2 max = 10.9 vs. 17.2 ml/kg/min), greater diameter of the left
atrium (49.9 vs. 45.9 mm) and decreased end-diastolic volume (LVEDV = 159.5 vs. 183.7 ml),
less frequent occurrence of LBBB (7.5% vs. 13.0%), higher overall mortality (28.3% vs. 17.1%),
and  more frequent rehospitalizations (15% vs. 8%). In patients with persistent AF (40%) with
HR < 75/min the mortality was 29% and was statistically significantly lower than in patients
with HR > 75/min in whom it was 54%.
Conclusions: Atrial fibrillation in patients with systolic heart failure is a disadvantageous, but
not independent risk factor. In patients with persistent atrial fibrillation the control of heart rate
< 75/min was associated with significant decrease in mortality. (Folia Cardiol. 2006; 13: 503–510)




Atrial fibrillation (AF) is a common form of ar-
rhythmia. It is found in over 5% of people above
69 years of age and in 10% of the population above
80 years of age [1]. It is usually associated with the
presence of organic heart disease, not uncommon-
ly being one of  the complications of arterial hyper-
tension. Among other deseases where atrial fibril-
lation comes very often for is rheumatic disease,
valvular heart disease, myocardial infarction, hyper-
thyreosis, pericarditis and myocarditis, alcohol in-
toxication, dyselectrolitaemia, and ecclampsia. The
AF is observed in 10% of patients with systolic heart
failure (SHF) with NYHA class II and in 50% of class
IV patients [2].
The assessment of the clinical significance of
atrial fibrillation in patients with systolic was the
subject of prior research. Both in healthy and in
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damaged myocardium the function of left ventricle
was deteriorated in patients with diagnosed AF [3].
It is a result of loss of synchronization of the con-
traction of the myocardium, worsening of contrac-
tile function of the atria, disturbance in excretion
of neurohormonal factors and dysfunction of the
valves. The loss of synchronic mechanical function
of the atria results in a decrease of stroke volume
of the left ventricle even up to 30% [4], and an in-
adequate response of the ventricles may result in
development of cardiomyopathy (so called tachyar-
rhythmia-induced cardiomyopathy) [5]. It results in
decreased parameters of exercise performance in
patients with atrial fibrillation and systolic heart fail-
ure comparing to patients with SHF and sinus rhythm
[6]. This is of vital importance for the progression of
functional failure of the myocardium, what may result
in worse prognosis of the patients with systolic heart
failure. However, there are discrepancies in availa-
ble literature regarding the influence of atrial fibrilla-
tion on the long-term follow-up (including mortality)
in patients with diagnosed SHF [7].
The aim of this study was to compare the clin-
ical presentation of patients with systolic heart fail-
ure and concomitant paroxysmal or persistent atri-
al fibrillation with patients with systolic heart fail-
ure and sinus rhythm, considering especially:
— echocardiographic evaluation of left ventricu-
lar parameters (EF, LVEDV, LVEDd, LVESd)
and maximal oxygen consumption per minute
(VO2 max) in spiroergometric test;
— the frequency of thromboembolic events;
— the significance of the control of heart rhythm
< 75/min in therapy of persistent AF in pa-
tients with systolic heart failure;
— the overall long-term prognosis.
Methods
Study population
There were 152 patients included in this study
(38 females and 114 males), aged 31 to 98 (mean
age was 65 years) hospitalized in the Department
of Coronary Heart Disease CMUJ between June
1997 and May 2002 with diagnosed systolic heart
failure (EF < 40%). The cases of left ventricular
failure in course of: acute myocardial infarction,
acute metabolic and endocrinologic disorders and
patients with diagnosed valvular heart disease were
excluded from the study.
From the qualified patients two groups were
formed:
— group I — patients with persistent or paroxys-
mal atrial fibrillation confirmed by electrocar-
diography — 53 patients: 14 women (aged
59 to 88) and 39 men (aged 56 to 98); mean age
was 69 years;
— group II — patients without history of atrial
fibrillation — 99 patients: 24 women (aged
44 to 86) and 75 men (aged 31 to 85); mean age
was 62 years.
In group I, paroxysmal (self-limiting) or persist-
ent atrial fibrillation was diagnosed. The diagnosis
and classification was based on ACC/AHA/ESC
guidelines from 2001 [8]. Initially, in every patient
the following parameters were analysed.
Clinical, ECG, and imaging variables
The following tests’ results and clinical data
were obtained in studied patients:
1. Electrocardiography at rest, including:
— presence of left bundle branch block (LBBB),
possibly 2-bundle block;
— rate of the ventricles (when persistent AF was
present).
2. Echocardiography, especially including:
— left ventricular ejection fraction (EF, %);
— end-diastolic (LVEDd) and end-systolic
(LVESd) diameter of the left ventricle [mm];
— end-diastolic volume of the left ventricle
(LVEDV) [ml].
All the measurements were performed using
the same echocardiographic equipment (ACUSON).
3. Excercise performance was measured through
maximal minute oxygen consumption in spiro-
ergometric test (VO2 max in ml/kg/min) — cal-
culated according to Naughton protocol, re-
stricted by occurrence of clinical signs or lack
of increase in oxygen consumption.
4. Presence of arterial hypertension.
Clinical endpoints
Information on the frequency of following pro-
cedures or events was acquired in both groups:
— implantation of a pacemaker.
— performing coronary arterial by-pass grafting
(CABG) or heart transplantation;
— re-hospitalization for cardiac causes during pe-
riod of observation;
— occurrence of cerebral embolism in course of
disease;
— death (main end-point).
The period of observation was 342 to 2315
days; mean period of observation was 936 days.
The analysis of the data referring to the follow-up
period was performed based on the information from
a survey conducted among the patients and their fam-
ilies. Patients consented to participate in the study.
505
Rafał Grzybczak et al., Atrial fibrillation as a prognostic factor in patients with systolic heart failure
www.foliacardiologica.eu
Statistical analysis
In statistical analysis the following tests were
used: Chi Square Pearson test, Chi Square Yates
test, as shown above with Fisher correction for
small groups, T-Student test and U-Mann-Whitney
test. The association between studied variables and




and ECG and ECHO findings
Atrial fibrillation in the examined patients (ei-
ther paroxysmal or persistent) occurred in 53 sub-
jects (35%). It was observed most often in patients
with NYHA class IV patients (58%). In class II
NYHA patients AF was found in 33% of patients,
and in class III patients in 29% (Table 1).
In group of patients with AF, 18 patients (34%)
had NYHA class II, class III was found in 22 patients
(41.5%), class IV in 13 patients (24.5%). In group II
(without AF), NYHA class II was found in 34 pa-
tients (34.3%), class III in 54 patients (54.5%), and
11 patients (11.1%) class IV. The causes of heart
failure were similar in both groups, however in the
AF group there were more cases of unknown or
questionable etiology (9.4% vs. 3.1%). Age and per-
centage of men and women in both groups was not
different between those groups (Table 2).
The SHF patients with AF had clinical signs of
advanced heart failure (NYHA IV) more often when
compared to patients with sinus rhythm (24.5% vs.
11.1%). The AF patients did not differ from patients
with sinus rhythm regarding frequency of hyperten-
sion (66% vs. 55%, respectively).
In the analysis of left ventricular function, the
EF in the AF patients (EF = 33.9%) was lower than
Table 1. Prevalence of atrial fibrillation in rela-
tionship to the NYHA class.
NYHA Number of Occurrence of
class  patients atrial fibrillation
II 52 17 (33%)
III 76 22 (29%)
IV 24 14 (58%)
Table 2. Baseline characteristics of patients with (group I) and without (group II) atrial fibrillation (AF).
Parameter Group I (SHF with AF) Group II (SHF without AF) p
Number of patients 53 (35%) 99 (65.1%)
Mean age (SD) years 69 (11.2) 62 (11.5) NS
Number of women years 14 (26.4%) 24 (24.2%) NS
Mean age of women (SD) years 71.86 (9.7) 63.25 (9.1) NS
Number of men 39 (73.6%) 75 (75.7%) NS
Mean age of men (SD) years 67.91 (11.7) 61.73 (12.2) NS
NYHA class:
   II 18 (34%) 34 (34.3%) NS
   III 22 (41.5%) 54 (54.5%) NS
   IV 13 (24.5%) 11 (11.1%) < 0.05
Heart failure etiology:
   ishaemic cardiomyopathy 27 (51%) 54 (54.4%) NS
   hypertrophic cardiomyopathy 21 (39.6%) 42 (42.4%) NS
   other* 5 (9.4%) 3 (3.1%) < 0.05
Arterial hypertension 35 (66%) 54 ( 55%) NS
VO2 max [ml/kg/min] 10.9 17.2 < 0.05
Ejection fraction (%) 33.9 37.3 NS
End-diastolic diameter of the left ventricle [mm] 56.9 61.0 NS
End-systolic diameter of the left ventricle [mm]  42.1 46.9 NS
End-diastolic volume of the left ventricle [ml]  159.5 183.7 < 0.05
Left atrium diameter [ml] 49.9 45.9 < 0.05
Presence of the left bundle branch block 4 (7.5%) 13 (13%) < 0.05
*Including etiologically unconfirmed, cardiomyopathies of questionable etiology; VO2 max — maximal oxygen consumption per minute in spiroergometric
test; SHF — systolic heart failure
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the EF in non-AF patients (EF = 37.3%). Despite
the marked tendency, those differences were sta-
tistically non-significant. There were no statistically
significant differences in LVEDd (56.9 mm in AF
patients vs. 61.0 mm in non-AF patients) and in
LVESd (42.1 mm vs. 46.9 mm, respectively). How-
ever, when comparing to patients without AF, the
diameter of the left atrium was greater (49.9 mm
vs. 45.9 mm) and LVEDV was lower (159.5 ml vs.
183.7 ml) the AF patients.
In the spiroergometric test of the exercise ef-
ficacy of the myocardium, the oxygen consumption
in AF patients was on the average 10.9 ml/kg/min,
and was statistically significantly lower than the
value reached in patients without history of AF
episodes (17.2 ml/kg/min). In the ECG, in 7.5%
(n = 4) of patients with AF the LBBB was found.
In the non-AF patients, this conduction disorder oc-
curred in 13% (n = 13) of patients (p < 0.05).
Clinical endpoints
The analysis of end-points (Table 3) showed
that the patients with AF required more frequent
hospitalizations for cardiac causes (in 15% of pa-
tients) when compared to patients without AF (8%).
There were no significant differences stated be-
tween the AF and non-AF patients when consider-
ing the frequency of CABG, 5.6% vs. 9%, respec-
tively; the frequency of stroke (with various neu-
rological consequences): 7.5% vs. 8%; the number
of pacemaker implantations: 18.8% vs. 14%.
In patients with concurrent AF and hyperten-
sion, a stroke episode occurred in 4 patients (11.5%).
In patients with sinus rhythm and without hyper-
tension same complications in the evaluated peri-
od occurred in 2 (4.5%) patients (p < 0.05).
The mortality in the AF group was 28.3%
(n = 15). It was statistically significantly higher than
mortality in the same period in patients with sinus
rhythm (17.1%; n = 17).
Type of atrial fibrillation:
persistent vs. paroxysmal
Among group I patients, clinically persistent
atrial fibrillation was identified in 21 patients
(39.6%), aged from 56 to 98 (4 women, 17 men;
mean age 64 years). In analysis of the level of systo-
lic insufficiency of those patients we found, that
3 patients (14.3%) had clinical signs of NYHA
class II, 13 patients (62%) — NYHA class III, and
5 subjects (23.7%) — NYHA class IV. Paroxysmal
atrial fibrillation occurred in 32 patients (10 wom-
en, 22 men) aged 54 to 84 (mean age 72 years). In
NYHA class II there were 16 patients (50%), in 8 in
each in both class III and IV groups (25%). A de-
tailed analysis is shown in Table 4.
Patients with persistent AF had higher ejec-
tion fraction (EF = 38.4%) in echocardiographic
evaluation than patients with paroxysmal AF
(EF = 36.6%). However, this difference was sta-
tistically non-significant. Also in such parameters
as LVEDd (57.7 mm in the group with persistent
AF vs. 56.9 mm for patients with paroxysmal AF),
LVESd (43.2 mm vs. 41.1 mm, respectively) and
LVEDV (162.8 ml vs. 155.9 ml) there were no sig-
nificant differences. However, in patients with
persistent AF the left atrial diameter was signif-
icantly greater (54.3 mm) in comparison with
its dimensions in patients with paroxysmal AF
(45.7 mm).
The patients with persistent AF were also
characterized by a lower exercise performance
(VO2 max = 8.2 ml/kg/min) when compared to patients
with paroxysmal AF (VO2 max = 11.8 ml/kg/min;
p < 0.05).
In the analysed ECG, beside the records of AF
there was LBBB found in 2 (9.5%) patients with
persistent and in 2 (6.25%) patients with paroxys-
mal AF (p = non-significant).
The pacemaker implantation procedure was
performed in 5 (23.8%) of patients with persistent
Table 3. Endpoints during long-term follow up in the two groups.
Parameter Group I (SHF with AF) Group II (SHF without AF) p
Pacemaker implantation 10 (18.8%) 14 (14%) NS
Coronary arterial by-pass grafting 3 (5.6%) 9 (9%) NS
Arterial hypertension + stroke 4 (11.5%) 6 (11.1%) NS
Stroke 4 (7.5%) 8 (8%) NS
Cardiac rehospitalizations 8 (15%) 8 (8%) < 0.05
Mortality 15 (28.3%) 17 (17.1%) < 0.05
SHF — systolic heart failure; AF — atrial fibrillation
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AF and in 5 (15.6%) with paroxysmal AF. During
the period of observation, the CABG was per-
formed in 2 (9.5%) patients with persistent and in
1 (3.1%) patient with paroxysmal atrial fibrillation.
In both cases, those differences were statistically
significant.
Two patients with persistent AF (9.5%) under-
went a stroke; in the same period of time this com-
plication occurred in two patients (6.3%) with par-
oxysmal AF. Every patient who had a stroke, had
also arterial hypertension. Those differences were
statistically insignificant, however we can speak of
a tendency to higher occurrence of strokes in pa-
tients with persistent AF.
During the period of observation, three (14.3%)
patients with persistent AF and five patients (15.6%)
with paroxysmal AF were rehospitalised (at least
once) for cardiac causes. The frequency of those
incidents did not distinguish statistically both sub-
groups.
During the period of observation, there was
a significantly higher mortality of patients with per-
sistent AF: 42.9% (n = 9) comparing to patients
with paroxysmal AF: 18.8% (n = 6).
A significantly higher mortality in patients with
persistent atrial fibrillation (54%) was observed
when heart rate was > 75/min. In patients with
persistent AF, in whom the heart rate in ECG was
< 75/min, the mortality was 28.6% (Table 5).
In the performed univariate and multivariate
analyses only age > 60 years, ejection fraction of
the left ventricle below 30% and hypertension were
independent prognostic risk factors for predicting
mortality in the examined group of patients with
systolic heart failure. Atrial fibrillation did not reach
significance in neither univariate nor multivariate
model (Table 6, 7).
Discussion
The risk of cardiac arrhythmias, including atrial
fibrillation, increases with age. This arrhythmia may
result in a decrease of hemodynamic parameters of
heart function by impairing the filling phase of the
ventricles, valvular function, as well as secretion of
mediators that disturb the neurohormonal stimula-
tion of the myocardium [9–12].
Older age influences significantly an impair-
ment of heart function as a result of various chang-
es undergoing in the myocardiocytes, what is man-
ifested clinically by features of it’s insufficiency. It
has been found in the present study that in NYHA
class IV patients atrial fibrillation occurred in more
than half of the patients (58%). In the NYHA class II
patients, atrial fibrillation occurred in 34% of patients.
That is more frequent than in previous study [2].
From the analysed echocardiographic parame-
ters only the diameter of the left atrium and LVDEV
Table 4. Comparison of patients with persistent and paroxysmal atrial fibrillation (AF) — basic characteristic
Parameter Persistent AF Paroxysmal AF p
Number of patients 21 (39.6%) 32 (60.4%)
Number of women 4 (19%) 10 (31%) < 0.05
Number of men 17 (81%) 22 (69%) < 0.05
Mean age (SD) years 64.47 (12.6) 72.31 (9.0) NS
Mean age of women (SD) years 69.5 (7.1) 72.8 (10.8) NS
Mean age of men (SD) years 63.29 (13.5) 72.8 (8.3) NS
NYHA class:
II 3 (14.3%) 16 (50%) < 0.05
III 13 (62%) 8 (25%) < 0.05
IV 5 (23.7%) 8 (25%) NS
VO2 max [ml/kg/min] 8.2 11.8 < 0.05
Ejection fraction (%) 38.4 36.6 NS
Diastolic diameter of left ventricular [mm] 57.7 56.9 NS
Systolic diameter of left ventricular [mm] 43.2 41.1 NS
End-diastolic volume of the left ventricle [ml] 162.8 155.9 NS
Left atrium diameter [mm] 54.3 45.7 < 0.05
Presence of the left bundle branch block 2 (9.5%) 2 (6.25%) NS
Arterial hypertension 14 (66.6%) 21 (65.6%) NS
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distinguished significantly the patients with AF
from the patients with sinus rhythm. Those chang-
es may be explained by dilation of mechanically in-
sufficient atria (LA diameter) and shortening of the
ventricle filling period when heart evolutions came
quickly one after another (LVEDV). The expected
difference between ejection fraction in both groups
did not reach statistical significance, however in the
AF patients its values were lower.
Based on oxygen consumption in the spiroer-
gometric test, we observed a lower functional per-
formance in patients with concurrent AF in com-
parison with patients with sinus rhythm. The val-
ues of VO2 max were lower by 27% in AF patients.
This corresponds with our hypothesis and with pre-
vious research [13].
There was no increase in frequency of cerebral
embolic complications in AF patients compared to
Table 7. Independent risk factors of death in the examined patients with systolic heart failure
— multivariate analysis.
Parameters Odds ratio 95% confidence interval p
Age > 60 years 9.16 2.73–30.75 < 0.0005
Left ventricular ejection fraction < 30% 3.57 1.46–8.73 < 0.01
Arterial hypertension 0.29 0.12–0.72 < 0.01
Table 5. Comparison of patients with persistent and paroxysmal atrial fibrillation (AF) — long-term follow-up
results
Parameter Persistent AF Paroxysmal AF p
Pacemaker implantation 5 (23.8%) 5 (15.6%) < 0.05
Coronary arterial by-pass grafting 2 (9.5%) 1 (3.1%) < 0.05
Atrial hypertension + stroke 2 (14.3%) 2 (9.5%) NS
Stroke 2 (9.5%) 2 (6.3%) NS
Cardiological  rehospitalization 3 (14.3%) 5 (15.6%) NS
Mortality among patients with HR < 75 3 (28.6%)
Mortality of patients with HR > 75 6 (54%)
Mortality 9 (42.9%) 6 (18.8%) < 0.05
VO2 max — maximal oxygen consumption per minute in spiroergometric test; HR — heart rate in min
Table 6. Prognostic significance of studied parameters for predicting the risk of death in patients with
systolic heart failure in univariate analysis.
Parameter Odds ratio 95% confidence interval p
Age (years) 1.08 1.03–1.13 0.001
Age > 60 years 5.84 1.92–17.81 0.002
NYHA functional class 1.61 0.93–2.77 0.085
Atrial fibrillation 1.56 0.71–3.41 0.261
LVEF 0.98 0.94–1.03 0.512
LVEF< 30% 3.16 1.41–7.1 0.005
Diabetes 0.87 0.35–2.14 0.757
Left bundle branch block 0.85 0.26–2.78 0.789
CABG in anamnesis 0.8 0.16–4.02 0.788
Past myocardial infarction 0.78 0.35–1.73 0.541
Arterial hypertension 0.55 0.25–0.89 0.041
Past stroke 0.19 0.02–1.55 0.119
LVEF — left ventricular ejection fraction; CABG — coronary arterial by-pass grafting
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sinus rhythm patients found during follow-up. Perhaps
it is a result of a relatively short period of observa-
tion, but also of a successful antithrombotic preven-
tion. There has been a few large clinical trials con-
ducted lately dedicated to occurrence of stroke in
course of atrial fibrillation (AFFIRM, RACE, STAF).
New, more exact biochemical markers of increased
risk of neurological complications in AF patients are
also searched for [14–17].
In the examined group of patients with SHF,
the risk of embolic events was significantly higher
when atrial fibrillation occurred (especially persistent)
as well as when hypertension was present — in the
non-AF and non-hypertension patients the ishae-
mic episodes in the central nervous system were
less frequent.
Diagnosing persistent AF in patients with
systolic heart failure proved to be an additional risk
factor worsening the prognosis and impairing left
ventricular function. Persistent AF was observed
more often in patients with severe heart failure
(NYHA class IV), what may be a result of the ex-
tent of myocardial damage (fibrosis), what has in
consequence morphologic and electric remodelling
of the myocardium [18]. In patients with persistent
atrial fibrillation, as proved in the study, one may
expect a need for more frequent hospitalizations,
coronary arterial by-pass grafting operations and
pacemaker implantation procedures. In this study
it was proved that the prognosis of patients with
concurrent atrial fibrillation is worse, however the
predictive independence of this factor has not been
proven. However, the predictive value and inde-
pendence has been proven in case of previously
acclaimed risk factors of death of the SHF patients:
low ejection fraction of the left ventricle and older
age. It seems to be suitable to consider the atrial
fibrillation (according to observations of the over-
all population) a sign of changes occurring in the
aging myocardium and as such, through the de-
scribed mechanisms, contributes to progression of
cardiac insufficiency, turning to be a marker of its
dysfunction (increase in frequency of the occur-
rence of atrial fibrillation in higher NYHA classes).
Although according to the presented results atrial
fibrillation can be considered an “old people’s sick-
ness”, it does not reduce the meaning of the fact
that the occurrence of this arrhythmia is associat-
ed with worse prognosis.
It is interesting to find arterial hypertension as
beneficial prognostic factor in patients with systol-
ic heart failure. This apparently paradoxal observa-
tion may be explained perhaps by potentially greater
hemodynamic reserves of patients with hyperten-
sion, and what is a consequence of this — a possi-
bility for a more aggressive, full-dosed pharmaco-
therapy, as recommended in randomised clinical
trials. This observation undoubtedly requires fur-
ther studies.
In patients with persistent atrial fibrillation,
regardless of a degree of heart failure it has been
beneficial to maintain heart rate < 75/min. This
result confirmes the validity of increasingly more
often postulated possibility of pharmacological ther-
apy of persistent and fixed AF [19] — at least in
some patients [20].
The mutual dependence of factors determin-
ing the clinical presentation of patients with systo-
lic heart failure and atrial fibrillation also seems to
be interesting: on one hand, damaged myocardium
predisposes to occurrence of arrhythmia, on the
other hand atrial fibrillation through the described
before mechanisms may result in heart failure
(“tachyarrhythmia-induced cardiomyopathy” — this
is perhaps the source of higher percentage of SHF
of unknown etiology in patients with AF?). Both
variants of the “vicious circle” of the sequence of
events result in an identical clinical picture, what
may cause difficulties in finding the initial cause of
the illness [21].
It should be considered also that in the elderly
population (majority of patients in this study) even
30–40% of AF incidents are asymptomatic, and only
1 per each 12 episodes of uncharacteristic palpita-
tions in cardiac region is further diagnosed [22].
Perhaps, with a detailed clinical history, more fre-
quent ECG, and 24-hour heart rhythm monitoring
the role of this arrhythmia as a factor of heart failure
progression would prove to be even more valuable.
Conclusions
1. Atrial fibrillation in patients with systolic heart
failure is a disadvantageous, but not independ-
ent risk factor of outcome.
2. Atrial fibrillation is a common arrhythmia in pa-
tients with systolic heart failure (over 1/3 of
patients examined), indicating advanced myo-
cardial damage and decreasing cardiac function,
especially in patients with persistent AF.
3. Patients with atrial fibrillation have more fre-
quent cardiac hospitalizations than patients
with sinus rhythm, and in case persistent AF
was present required also a greater number of
CABG and/or pacemakers implantations.
4. In patients with persistent atrial fibrillation the
control of heart rate < 75/min was associated
with significant decrease in mortality.
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